Literature DB >> 27160123

Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer.

L-L Jing1, X-M Mo.   

Abstract

OBJECTIVE: The present study was designed to explore expression and prognostic value of miR-485-5p in patients with gastric cancer. PATIENTS AND METHODS: We determined the expression level of miR-485-5p in 132 cases of paired GC and adjacent non-tumor tissues by quantitative real-time PCR (qRT-PCR). The relevance of miR-485-5p expression to the clinicopathological factors was assessed. Overall survival (OS) was examined using Kaplan-Meier curves and the Cox proportional hazards regression model.
RESULTS: The expression of miR-485-5p was significantly down-regulated in GC tissues compared with adja-cent normal tissues (p < 0.01). MiR-485-5p expression was positively correlated with larger tumor size (p = 0.003), deeper invasion depth, (p = 0.005), positive lymph node metastasis (p = 0.039), advanced tumor-node-metastasis (TNM) stage (p = 0.017). Patients survival analysis showed that a clear positive correlation between miR-485-5p expression level and survival time of gastric cancer patients (p < 0.001). Multivariate analyses confirmed that a low level of miR-485-5p expression was an independent predictor of poor prognosis in GC patients.
CONCLUSIONS: Expression level of miR-485-5p serves as a novel biomarker for the overall survival of patients with gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27160123

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  17 in total

1.  A tumor-suppressive microRNA, miRNA-485-5p, inhibits glioma cell proliferation and invasion by down-regulating TPD52L2.

Authors:  Jin Yu; Shi-Wen Wu; Wei-Ping Wu
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Long non-coding RNA LINC00707 acts as a competing endogenous RNA to enhance cell proliferation in colorectal cancer.

Authors:  Han Wang; Hairong Luan; Tao Zhan; Xia Liu; Jie Song; Haibing Dai
Journal:  Exp Ther Med       Date:  2019-12-19       Impact factor: 2.447

Review 3.  Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.

Authors:  Alti Dayakar; Kumar D Shanmukha; Suresh K Kalangi
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.742

4.  Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.

Authors:  Maria Rovira-Rigau; Giulia Raimondi; Miguel Ángel Marín; Meritxell Gironella; Ramon Alemany; Cristina Fillat
Journal:  Mol Ther       Date:  2018-09-27       Impact factor: 11.454

5.  Calcitonin gene‑related peptide induces IL‑6 expression in RAW264.7 macrophages mediated by mmu_circRNA_007893.

Authors:  Tian Deng; Lan Yang; Zhichao Zheng; Yuanjing Li; Wen Ren; Caijuan Wu; Lvhua Guo
Journal:  Mol Med Rep       Date:  2017-10-12       Impact factor: 2.952

6.  hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma.

Authors:  Xiu-Juan Lin; Chang-Li He; Ting Sun; Xue-Jing Duan; Yi Sun; Shi-Jiang Xiong
Journal:  Int J Mol Med       Date:  2017-05-16       Impact factor: 4.101

7.  LINC01224 Exhibits Cancer-Promoting Activity in Epithelial Ovarian Cancer Through microRNA-485-5p-Mediated PAK4 Upregulation.

Authors:  Shujian Xing; Yaqi Zhang; Jing Zhang
Journal:  Onco Targets Ther       Date:  2020-06-16       Impact factor: 4.147

8.  Reduced levels of miR-485-5p in HPV-infected cervical cancer promote cell proliferation and enhance invasion ability.

Authors:  Yuanyuan Dai; Fengyan Xie; Yan Chen
Journal:  FEBS Open Bio       Date:  2020-06-30       Impact factor: 2.693

9.  Prognostic value of microRNAs in gastric cancer: a meta-analysis.

Authors:  Yue Zhang; Dong-Hui Guan; Rong-Xiu Bi; Jin Xie; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-06-21

10.  The role of miR-485-5p/NUDT1 axis in gastric cancer.

Authors:  Jingjing Duan; Haiyang Zhang; Shuang Li; Xinyi Wang; Haiou Yang; Shunchang Jiao; Yi Ba
Journal:  Cancer Cell Int       Date:  2017-10-17       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.